In This Section


What’s next for drug discovery and development

Tuesday, September 12, 2023


Register for on demand viewing

The next decade promises to be a time of dramatic change for the cancer research community in terms of how new therapies will be discovered and developed. In keeping with advances in data science, drug discovery will be one of the areas of cancer research most significantly transformed through the application of artificial intelligence (specifically machine and deep learning). Enormous amounts of data, and data integration, will be required to power this information-driven transition, but the search for new cancer drug (and biologic) targets is well underway. These new approaches will present unique challenges for all aspects of drug development, including clinical trials and the regulatory review of these new agents. This AACR Patient Advocate Forum will explore what to expect in the months and years ahead in terms of the rate of progress for these new approaches. 

Should we expect artificial intelligence (AI) to transform the field of drug discovery and enable an entirely new generation of safe, and more effective therapies for cancer—or is this too much to hope for at this point? Join us as we meet some of the pioneers in the field who will share their opinions and thoughts on the possible.


Anna D. Barker, PhD, FAACR, Ellison Institute for Transformative Medicine


Howard Brown, Paltown Foundation

Paul Workman, FMedSci, FRS, The Institute of Cancer Research, London

Frank McCormick, PhD, FRS, FAACR, University of California, San Francisco

Program Agenda Speaker Bios

AACR Patient Advocate Forums

The AACR is committed to providing educational programming to patients with cancer and patient advocacy communities to support their collective mission to find cures for all cancers. AACR Patient Advocate Forums invite leaders from patient advocacy, academia, industry, and healthcare communities to discuss pressing topics and the latest discoveries in cancer research. These virtual forums are provided quarterly at no cost to attendees and open to the public. 


Bristol Myers Squibb Daiichi-Sankyo Genmab